Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951
about
Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomasIntrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORSynergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.Relationships between PTEN gene mutations and prognosis in glioma: a meta-analysis.Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation.Something old and something new about molecular diagnostics in gliomas.Loss of CIC and FUBP1 expressions are potential markers of shorter time to recurrence in oligodendroglial tumors.Personalized surgical therapy.Prognostic value of Ki67 index in anaplastic oligodendroglial tumours--a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
P2860
Q24194645-E97EDC04-2099-40E7-BFC2-88AD64773BF1Q34523475-5109C978-8965-44A7-A0F4-64B4D3065919Q34848038-33BE377D-28B4-4D03-8FAE-F8381C3FB0E3Q35140496-AFC32FFA-0AE5-45D7-AF0B-89EBCAAE5AB6Q36618241-B92622D0-2CBA-4FBD-A451-CE0D6539A38DQ36693953-516AE28C-1C1E-41AC-BD74-593B6A58A081Q43238974-6278BFAB-F598-48A3-89CF-F4BCD883058CQ43442484-2AE62806-431F-4652-B731-EE0A57F4FD54Q48365755-80A1917C-8F0F-4F9D-8948-B8F9D0C15DE3Q48659691-77F83FD1-4D99-470E-8EF8-3719D1F075D5
P2860
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Genomic aberrations associated ...... he EORTC phase III trial 26951
@ast
Genomic aberrations associated ...... he EORTC phase III trial 26951
@en
Genomic aberrations associated ...... he EORTC phase III trial 26951
@nl
type
label
Genomic aberrations associated ...... he EORTC phase III trial 26951
@ast
Genomic aberrations associated ...... he EORTC phase III trial 26951
@en
Genomic aberrations associated ...... he EORTC phase III trial 26951
@nl
prefLabel
Genomic aberrations associated ...... he EORTC phase III trial 26951
@ast
Genomic aberrations associated ...... he EORTC phase III trial 26951
@en
Genomic aberrations associated ...... he EORTC phase III trial 26951
@nl
P2093
P2860
P50
P1476
Genomic aberrations associated ...... he EORTC phase III trial 26951
@en
P2093
Catherine Carpentier
Cyril Dalmasso
Jean-Yves Delattre
Johan M Kros
Johannes Teepen
Judith Jeuken
Karima Mokhtari
Khê Hoang-Xuan
Marc Sanson
Martin van den Bent
P2860
P2888
P304
P356
10.1007/S11060-010-0380-9
P577
2010-09-06T00:00:00Z
P5875
P6179
1001398495